EGFR-Targeted Quinazoline Clubbed

Heterocycles as Anticancer Agents

21

Vivek Panwar, Kritika Mukherji, Manjunath Ghate, Deepak K. Jindal,

and Deepak Kumar

Abstract

Cancer is a multifactorial chronic disease cohorted with different protein kinases.

Epidermal growth factor receptor (EGFR) is the ligand-gated ion channel receptor

or protein kinase implicated in the regulation of various biochemical incidents

occurring in cell. Although EGFR has a variety of physiological roles, its over-

activation or mutational modifications at different exons result in oncogenesis.

Out of 52 Food and Drug Administration (FDA)-approved EGFR inhibitors for

different cancers, seven are quinazoline clubbed heterocyclic molecules.

Quinazolines are the medicinally active scaffolds in which nitrogen atoms are

present as a part of their heterocyclic ring system. Therefore, this chapter is

focussed on the EGFR-targeted quinazoline-based heterocycles.

Keywords

Cancer · Epidermal growth factor receptor (EGFR) · Quinazolines · Heterocycles ·

Food and Drug Administration (FDA)

V. Panwar · K. Mukherji · D. Kumar (*)

Department of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Shoolini University,

Solan, Himachal Pradesh, India

e-mail: guptadeepak002@gmail.com

M. Ghate

Department of Pharmaceutical Chemistry, Institute of Pharmacy, Nirma University, Ahmedabad,

Gujarat, India

D. K. Jindal

Department of Pharmaceutical Sciences, Guru Jambheshwar University of Science and

Technology, Hisar, Haryana, India

# The Author(s), under exclusive license to Springer Nature Singapore Pte

Ltd. 2022

R. C. Sobti, N. S. Dhalla (eds.), Biomedical Translational Research,

https://doi.org/10.1007/978-981-16-9232-1_21

387